Published in HIV Med on May 26, 2009
Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol (2012) 1.94
Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.80
Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. Addiction (2011) 1.50
Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS (2012) 1.18
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS One (2011) 1.15
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13
Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend (2011) 1.09
Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav (2013) 1.01
Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend (2012) 0.93
Illicit drug use is a significant risk factor for loss to follow up in patients with HIV-1 infection at a large urban HIV clinic in Tokyo. PLoS One (2013) 0.93
Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Policy Plan (2012) 0.91
Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ (2013) 0.89
High prevalence of illicit drug use in men who have sex with men with HIV-1 infection in Japan. PLoS One (2013) 0.86
Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review. AIDS Behav (2015) 0.85
Opioid substitution therapy in resource-poor settings. Bull World Health Organ (2011) 0.84
Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open (2015) 0.82
CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug users. Open Forum Infect Dis (2015) 0.80
Development of a Multi-Target Contingency Management Intervention for HIV Positive Substance Users. J Subst Abuse Treat (2016) 0.78
Residential Eviction and Risk of Detectable Plasma HIV-1 RNA Viral Load Among HIV-Positive People Who Use Drugs. AIDS Behav (2016) 0.77
Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era. Open Forum Infect Dis (2014) 0.77
Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). PLoS One (2015) 0.76
Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. AIDS (2016) 0.76
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study. Eur J Med Res (2011) 0.75
Cocaine Use May be Associated with Increased Depression in Persons Infected with HIV. AIDS Behav (2016) 0.75
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS One (2016) 0.75
Finding what works: identification of implementation strategies for the integration of methadone maintenance therapy and HIV services in Vietnam. Implement Sci (2016) 0.75
HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care (2017) 0.75
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet (1992) 4.42
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 4.31
Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet (1996) 4.22
Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite. N Engl J Med (1993) 3.75
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis (2011) 2.98
Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry (1988) 2.96
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics (2005) 2.94
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis (2006) 2.93
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis (2009) 2.78
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis (1987) 2.71
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis (2005) 2.58
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother (1985) 2.55
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis (2002) 2.46
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr (2013) 2.38
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis (2008) 2.35
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis (2005) 2.35
16S rRNA sequence diversity in Mycobacterium celatum strains caused by presence of two different copies of 16S rRNA gene. J Clin Microbiol (1998) 2.33
Health problems after travel to developing countries. J Infect Dis (1987) 2.31
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother (1985) 2.25
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Lessons from loricrin-deficient mice: compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein. J Cell Biol (2000) 2.22
DNA probes specific for Entamoeba histolytica possessing pathogenic and nonpathogenic zymodemes. Infect Immun (1989) 2.22
Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19
Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis (1987) 2.18
Two different 16S rRNA genes in a mycobacterial strain. J Clin Microbiol (1996) 2.17
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis (2003) 2.17
A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med (1994) 2.16
Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences. Infect Immun (1983) 2.15
Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood (2009) 2.15
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2010) 2.12
Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry (2009) 2.12
Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity (2001) 2.11
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med (2010) 2.05
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis (2012) 2.04
Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med (Berl) (2000) 2.04
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03
[HIV epidemic: an end to exceptional regulation? Response to the article which appeared under this title in the Revue médicale de la Suisse romande (112, 239-241, 1991)]. Rev Med Suisse Romande (1992) 2.02
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med (1991) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem (1997) 2.00
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis (2007) 1.98
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol (2007) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci U S A (2004) 1.97
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Quality of care and outcomes of adults with asthma treated by specialists and generalists in managed care. Arch Intern Med (2001) 1.96
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet (2003) 1.94
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis (2005) 1.93
Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J Immunol (1969) 1.91